Diagnosed prostate cancer cases across 8MM to hit 4.24 million in 2033

The rise is partly attributed to the increased survival rate due to modern medicine.

The burden of five-year diagnosed prevalent cases of prostate cancer is projected to increase annually at 3.10% to 4.24 million in 2033 across the eight major markets (8MM), said GlobalData.

The rise is partly attributed to the increased survival rate of patients due to modern medicine and underlying demographic changes in the respective markets.

Meanwhile, prostate-specific antigen (PSA) testing for screening is expected to impact the epidemiology of cancer cases, said Bishal Bhandari, Associate Director of Epidemiology at GlobalData.

“PSA screening can detect prostate cancer early, but it can also result in the detection of non-life-threatening tumours, causing unnecessary anxieties,” Bhandari added.

8MM = US, France, Germany, Italy, Spain, UK, Japan, and China